3-Methyl-5-brom-2-hydroxyacetophenon | 72422-80-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-Methyl-5-brom-2-hydroxyacetophenon
• 英文别名: 1-(5-Bromo-2-hydroxy-3-methylphenyl)ethanone
• CAS: 72422-80-1
• 化学式: C₉H₉BrO₂
• mdl: MFCD18294026
• 分子量: 229.073
• InChiKey: FYCJGBWDWQDUPT-UHFFFAOYSA-N

物化性质

• 熔点：
  78–79°C
• 沸点：
  299.7±40.0 °C(Predicted)
• 密度：
  1.508±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  3-Methyl-5-brom-2-hydroxyacetophenon 在 吡啶 、 盐酸 、 氢氧化钾 、 溶剂黄146 、 copper(ll) bromide 、 三氯氧磷 作用下， 以 吡啶 、 氯仿 、 乙酸乙酯 为溶剂， 反应 11.0h， 生成 3,6-dibromo-2-(2-methoxyphenyl)-8-methylchromen-4-one
  参考文献：
  名称：

  Mazumdar; Karmakar; Rangachari, Journal of the Indian Chemical Society, 1990, vol. 67, # 11, p. 911 - 913

  摘要：

  DOI：
• 作为产物：
  描述：

  4-(5-Bromo-2-hydroxy-3-methylphenyl)-1,3-dithiole-2-thione 在 sodium sulfide 作用下， 以 乙醇 为溶剂， 反应 1.0h， 生成 3-Methyl-5-brom-2-hydroxyacetophenon
  参考文献：
  名称：

  Reaction of 4-(2′-Hydroxyaryl)-1,3-dithiolium Salts with Sodium Sulfide. A Selective Synthesis of 2′-Hydroxyacetophenones

  摘要：

  The treatment of 4-(2'-hydroxyaryl)-2-(N,N-dialkylamino)-1,3-dithiolium perchlorates (1a-g) with sodium sulfide nonahydrate in ethanol at room temperature affords the corresponding 1,3-dithiole-2-thiones (2a-g). When these reactions are conducted in boiling ethanol, 2'-hydroxyacetophenones (3a-g) have been obtained in good to excellent yield. A tentative mechanism for the formation of 3a-g shows that this reaction is regioselective, this being established by the presence of hydroxyl group in 2'-position. That has been confirmed in a control experiment, 4-phenyl-2-(piperidin-1-yl)-1,3-dithiolium perchlorate affording a mixture of condensation products of acetophenone and phenylacetaldehyde, under similar reaction conditions.

  DOI：

  10.1081/scc-120022483

文献信息

• Spirocyclic derivatives as histone deacetylase inhibitors
  申请人：DAC S.r.l.

  公开号：EP2311840A1

  公开（公告）日：2011-04-20

  This invention is related to new histone deacetylase inhibitors according to the general formula (I), wherein: is a single or a double bond; m and n are independently zero or an integer from 1 to 4; p is zero or an integer from 1 to 3, with the proviso that when p is zero, n and m cannot be both 1; R is hydrogen; C1-C6 alkyl, optionally substituted by cycloalkyl, aryl or by heteroaryl; (CO)R2; (SO2)R3; cycloalkyl; aryl; or heteroaryl; R1 is halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy; X is CH2, oxygen or NR4; Y is CHR5 or NR6; Z is CR7R8 or C=R9; and R2, R3, R4, R5, R6, R7, R9, and R9 are as further defined in the specification; and pharmaceutical acceptable salts thereof.

  这项发明涉及新的组蛋白去乙酰化酶抑制剂，其通式为（I），其中：是一个单键或双键；m和n分别为0或1至4的整数；p为0或1至3的整数，但当p为0时，n和m不能同时为1；R为氢；C1-C6烷基，可选地被环烷基、芳基或杂环烷基取代；（CO）R2；（SO2）R3；环烷基；芳基；或杂环烷基；R1为卤素，C1-C6烷基，C1-C6卤代烷基，C1-C6烷氧基，C1-C6卤代烷氧基；X为CH2、氧或NR4；Y为CHR5或NR6；Z为CR7R8或C=R9；以及规范中进一步定义的R2、R3、R4、R5、R6、R7、R9和R9；以及其药用可接受的盐。
• SPIROCYCLIC DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS
  申请人：Varasi Mario

  公开号：US20120258949A1

  公开（公告）日：2012-10-11

  This invention is related to new histone deacetylase inhibitors according to the general formula (I), wherein: m and n are independently zero or an integer from 1 to 4; p is zero or an integer from 1 to 3, with the proviso that when p is zero, n and m cannot be both 1; R is hydrogen; C 1 -C 6 alkyl, optionally substituted by C 3 -C 8 cycloalkyl, C 6 -C 10 aryl or hetero(C 2 -C 9 )aryl; (CO)R 2 ; (SO 2 )R 3 ; C 3 -C 8 cycloalkyl; C 6 -C 10 aryl; or hetero(C 2 -C 9 )aryl; R 1 is halogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy; Y is CH 2 or NR 4 ; Z is C═R 5 ; and R 2 , R 3 , R 4 , and R 5 are as further defined in the specification; and pharmaceutical acceptable salts thereof.

  本发明涉及一种新的组蛋白去乙酰化酶抑制剂，其通式为(I)，其中：m和n独立地为0或1到4的整数；p为0或1到3的整数，但当p为0时，n和m不能同时为1；R为氢；C1-C6烷基，可选地被C3-C8环烷基，C6-C10芳基或杂环(C2-C9)芳基取代；(CO)R2；(SO2)R3；C3-C8环烷基；C6-C10芳基；或杂环(C2-C9)芳基；R1为卤素，C1-C6烷基，C1-C6卤代烷基，C1-C6烷氧基，C1-C6卤代烷氧基；Y为CH2或NR4；Z为C═R5；R2、R3、R4和R5如规范中进一步定义；以及其药学上可接受的盐。
• [EN] BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF<br/>[FR] COMPOSÉS PYRAZOLE CONTENANT DU BORE, COMPOSITIONS COMPRENANT CEUX-CI, MÉTHODES ET UTILISATIONS ASSOCIÉES
  申请人：BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC

  公开号：WO2022133420A1

  公开（公告）日：2022-06-23

  The present invention describes novel boron containing pyrazole compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus kinase (JAK) inhibitors and are useful in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described are methods of treating inflammation, auto-immune diseases, cancer, and other conditions that are susceptible to the inhibition of a Janus kinase by administering a compound herein described.

  本发明描述了新型含硼吡唑化合物或其药学上可接受的盐、包含它们的制药组合物以及它们的医学用途。本发明化合物具有作为Janus激酶（JAK）抑制剂的活性，并且在治疗或控制炎症、自身免疫性疾病、癌症和其他需要调节JAK的疾病和适应症中有用。还描述了通过给予本文所述化合物来抑制Janus激酶以治疗炎症、自身免疫性疾病、癌症和其他易受抑制Janus激酶的疾病和症状的方法。
• Banerji; Kumar; Saha, Journal of the Indian Chemical Society, 1985, vol. 62, # 7, p. 531 - 533
  作者：Banerji、Kumar、Saha、Mazumdar

  DOI：——

  日期：——
• Sarbaggya, D. P.; Rangachari, K.; Mazumdar, A. K. D., Journal of the Indian Chemical Society, 1981, vol. 58, p. 196 - 197
  作者：Sarbaggya, D. P.、Rangachari, K.、Mazumdar, A. K. D.、Banerji, K. D.

  DOI：——

  日期：——